Par Drugs & Chemicals Ltd (PAR) is currently trading at 134.37 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Par Drugs and Chemicals Limited manufactures Active Pharma Ingredients (APIs) and fine chemicals for both domestic and international markets, operating two facilities in Gujarat, India. The company focuses on a diversified portfolio with 12 APIs and 6 fine chemicals, expanding its market reach to approximately 16 countries. In 2021, Par Drugs expanded its production capacity by introducing a new manufacturing block, demonstrating potential growth in its existing product segments. The Bhavnagar facility is certified by food & drugs control administration, reflecting the company's commitment to maintaining high-quality production standards. Key customers include reputable names like Pfizer Limited and United Phosphorus Limited, indicating strong industry partnerships and reputation.

Over the past 52 weeks, Par Drugs & Chemicals Ltd has traded between a low of ₹78.05 and a high of ₹180.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Par Drugs & Chemicals Ltd has a market capitalization of approximately 174.04. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Par Drugs & Chemicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.01 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 174.04 Cr, Par Drugs & Chemicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Par Drugs & Chemicals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Par Drugs & Chemicals Ltd is 12.01. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

SEBI blocked the sale due to prima facie irregularities in valuation, shareholder communication, and the voting process. The deal was considered potentially detrimental to the interests of public shareholders.

SEBI halted the sale due to prima facie irregularities in the valuation of the business, shareholder communication, the voting process, and concerns that the deal was detrimental to public shareholders.